andarine
ANABOLIC · NONSTEROIDAL SARM · T½ NOT ESTABLISHED
also: S-4 · S4 · GTx-007
Andarine was the first SARM to enter human clinical trials, completing three phase 1 studies in 86 healthy volunteers before development was discontinued in favour of enobosarm. The stated reason for discontinuation was adverse visual disturbances observed during phase 1, which makes it one of the few compounds in this index abandoned for a specific documented toxicity rather than lack of commercial interest.
// our evidence grade — unedited
Andarine completed three phase 1 trials and was then abandoned by its developer specifically because of visual disturbances, with no published efficacy trial ever completed.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | Andarine (S-4, GTx-007) |
| cas | 401900-40-1 |
| formula | C19H18F3N3O6 |
| molar mass | 441.4 g/mol |
| purity | ≥ 98% HPLC |
| form | research solution |
| storage | Store the solution sealed, upright and protected from light. Reference solid material is held desiccated at -20 °C; stock solutions are aliquoted and frozen with freeze-thaw cycles minimised. |
| solubility | Lipophilic small molecule: soluble in DMSO and ethanol, poorly soluble in water. Lot-specific solubility is stated on the certificate of analysis. |
// select size
crypto payment · research use only · not for human consumption
// others in Anabolic & Receptor